Title: Epidemiology and Characteristics of MPXV Clade I cases in the WHO European Region, 2024-2025

Authors: Ioannis Karagiannis[1], Jeffrey Pires[1], Pana Akhmetniyaz[1], Olivier le Polain de Waroux[2], Bart Hoorelbeke[3], Bertrand Gagnière[4], Klaus Jansen[5], Chrysa Tsiara[6], Derval Igoe[7], Maria Rosaria Campitiello[8], Catharina van Ewijk[9], Vítor Cabral Veríssimo[10], Laura Santos Larrégola[11], Erik Sturegård[12,13], Céline Gardiol[14], Taliha Karakök[15], Gareth J. Hughes[16], Marc-Alain Widdowson[1]

This article is a preprint and has not been certified by peer review.

Author information and affiliations:

[1] Health Security Division, WHO Regional Office for Europe, Copenhagen, Denmark

[2] WHO Health Emergencies Programme, WHO headquarters, Geneva, Switzerland

[3] DG Preparedness and Response, Federal Public Service – Health, Food Chain Safety and Environment, Brussels, Belgium

[4] Santé Publique France, Rennes, France

[5] Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany

[6] National Public Health Organisation, Athens, Greece

[7] HSE – Public Health: National Health Protection Office Dublin, Ireland

[8] Head of the Department of Prevention, Research and Health Emergency, Ministry of Health, Italy

[9] National Institute for Public Health and the Environment, Bilthoven, the Netherlands

[10] Directorate-General of Health, Ministry of Health, Portugal

[11] Coordinating Centre for Health Alerts and Emergencies, Ministry of Health, Spain

[12] Department of Communicable Disease Control and Preparedness, Public Health Agency of Sweden

[13] Department of Translational Medicine, Faculty of Medicine, Lund University, Malmö, Sweden

[14] Section for Infection Control and Response Measures, Communicable Diseases Division, Federal Office of Public Health, Bern, Switzerland

[15] Department of Communicable Diseases, General Directorate of Public Health, Ministry of Health, Ankara, Türkiye

[16] Field Services, UK Health Security Agency, Leeds, United Kingdom

Contact author: Marc-Alain Widdowson widdowsonm@who.int

Abstract

BACKGROUND

On 14 August 2024, WHO Director-General declared a public health emergency of international concern (PHEIC) following a sharp increase in mpox cases linked to the emergence of monkeypox virus (MPXV) clade Ib. We characterise imported and autochthonous cases of MPXV clade I reported in the WHO European Region since August 2024.

METHODS

Between 14 August 2024 and 23 November 2025, we collected key information of MPXV clade I infections reported by member states of the WHO European Region through the International Health Regulations. We contacted reporting countries to collect, age, gender, travel history, most probable route of transmission, clinical course, number of contacts and type of exposure, and implemented control and prevention measures.

RESULTS

82 cases of MPXV clade I infection were reported, including one probable; 45 were imported and 37 were infections acquired in Europe. Almost all were typed as clade Ib, except for two clade Ia. Most imported cases with information reported heterosexual or close physical contact as possible exposure. Secondary transmission occurred in six households, and one healthcare worker was infected. Since October 2025, 17 autochthonous cases have been reported with a majority men who reported recent sexual contact with other men in Europe.

CONCLUSIONS

Imported cases of MPXV clade I infection were associated with limited household but the increase in autochthonous infections among men with recent sexual contact with other men suggests MPXV clade 1b may be endemic in Europe. Continued surveillance, case and contact investigation are needed to understand MPXV clade I epidemiology and drivers of possible sustained transmission in Europe.

Keywords: mpox; monkeypox virus; clade I; imported infections; household transmission; men who have sex with men; Europe; public health surveillance

Introduction

Mpox (formerly known as monkeypox) was first identified in humans in 1970 in the Democratic Republic of the Congo and, until recent years, only sporadic zoonotic infections with limited person-to-person transmission had been reported [1]. In 2003, the first cases of mpox outside Africa were documented in the United States during an outbreak in which 47 people were infected following exposure to prairie dogs which had been infected by rodents imported from Ghana [2]. Subsequently, several imported cases of mpox were reported in Israel, Singapore, the United Kingdom and the United States, but with little to no evidence of onward transmission [1, 3].

In 2020, the largest recorded outbreak of mpox (clade I) occurred in the Democratic Republic of the Congo [4] and in 2022, a global mpox epidemic caused by clade II prompted the World Health Organization (WHO) Director-General to declare a Public Health Emergency of International Concern (PHEIC) [5]. The monthly number of reported global cases peaked at approximately 30,000 cases in August 2022 [6], followed by a decline in cases globally and in Europe [7] and in May 2023 the PHEIC was lifted [8]. Since September 2023, the Democratic Republic of the Congo has seen a sharp increase in the reported number of mpox cases, linked to both the emergence of a distinct new strain, MPXV clade Ib, and a rise in cases caused by infection with previously circulating MPXV clade Ia [9]. Earlier evidence, including a 2022 meta-analysis, suggested that MPXV clade I may be associated with higher case-fatality than clade II [10, 11]. The newly identified clade Ib rapidly spread to neighbouring African countries and elsewhere. Initial reports from Democratic Republic of the Congo indicated sustained person-to-person transmission, including through heterosexual sex. For this reason, WHO declared mpox a PHEIC for a second time on 14 August 2024 [12], which was lifted in September 2025 [13]. The first case of MPXV clade Ib infection outside of Africa was reported by Sweden on the next day [14, 15]. Between January 2024 and 7 November 2025, 17 countries in the WHO African Region and 26 countries in all other regions have reported MPXV clade Ib cases have [6], with the European region reporting most MPXV clade I cases. Evidence of non-sexual transmission in both imported cases [16] and outbreaks in Africa [15, 17, 18] suggests that clade Ib could become endemic in Europe. As observed for clade IIb, this could occur either via sexual networks, or via non-sexual contact, such as prolonged skin-to-skin contact [19].

Rapid investigation of MPXV clade I cases and timely public health response are essential to prevent further spread, provide key data on the epidemiology of MPXV clade I and inform risk assessments for Europe and comparable settings worldwide. In this paper, we describe MPXV clade I cases reported in the WHO European Region since August 2024, as well as member states' response activities aimed at limiting transmission, to gain a better understanding of the characteristics and epidemiology of MPXV clade I cases in Europe.

Methods

Cases of MPXV clade I were reported to the WHO Regional Office for Europe by Member States, in line with WHO standing recommendations for mpox [20] and International Health Regulations [21]. We gathered information on each index case reported by Member States of the WHO European Region through IHR mechanisms between 14 August 2024 and 23 November 2025 including age, gender, travel history, possible exposures, most likely route of transmission, clinical course, number of contacts (and age when available) and type of exposure, and on implemented control and prevention measures. In addition to passive surveillance, the WHO Regional Office and the European Centre for Disease Prevention and Control (ECDC) actively engaged with national and regional public health authorities with follow-up phone calls in affected countries to verify case details and ensure consistency of reporting. To support early detection and improve response capacity and to ensure that all 53 Member States of the WHO European Region were aware and had capacity to detect possible mpox cases, the WHO Regional Office hosted a regional webinar for national surveillance officers with guidance on case definitions, notification procedures, and response strategies. The Regional Office also distributed mpox-specific investigation kits to facilitate specimen collection and laboratory confirmation where national capacity was limited.

Results

As of 23 November 2025, one probable and 81 confirmed cases of MPXV clade I infection have been reported to the WHO Regional Office for Europe; one case reported by Türkiye and one reported by the Republic of Ireland [22] were typed as clade Ia; two reported from Spain were typed as clade I (subclade information pending), and the remaining 77 were typed as MPXV clade Ib. The probable case reported by the Republic of Ireland was imported and had close contact with a subsequently confirmed case of MPXV clade Ib infection. One case with travel history to Asia initially notified as MPXV clade Ib was later found to be a

recombinant virus containing elements of both clade Ib and IIb [23]. Of the 82 cases, 45 were deemed to have contracted mpox overseas in the 21 days before symptom onset and were thus assessed as imported. Likely countries of infection included Uganda (N=11), Democratic Republic of the Congo (N=6), Rwanda (N=5), the United Republic of Tanzania (N=5), Kenya (N=3), the United Arab Emirates (N=3), Thailand (N=2), the Netherlands (N=2), Malaysia (N=1), Pakistan (N=1), Viet Nam (N=1), Angola (N=1), "East Africa" (N=1), and "Central Africa" (N=1). One case had travelled to Rwanda, Uganda, and United Republic of Tanzania within 21 days before symptom onset, and one case had travelled to both Egypt and United Arab Emirates, but case history suggests transmission most likely occurred in the United Arab Emirates. Of the 37 cases infected in Europe, 17 were secondary cases of one of seven imported cases or an already known autochthonous case, and a further 20 cases were not related to any reported case (Figure 1).

Of the 45 imported cases, 43 were male and two were female; age was known for 38 cases, and the 10-year age group was known for six; the median age was 36.5 years (range 18-64 years). The most likely route of infection, as determined from case interviews performed by reporting member states, was assessed as sexual contact (where known, predominately heterosexual) for 25 of 45 imported cases (55.6%), other intimate physical contact (e.g. massage, sauna services) for four (8.89%) and unknown for the remaining 16 (35.6%) cases (Table 1).

One child needed hospitalisation for treatment of severe pain caused by the disease. No other patients needed hospitalisation for clinical reasons. As of 23 November 2025, all patients had recovered.

Of the 37 cases infected in Europe, 13 (35.1%) were household contacts of imported cases. Of these 13 secondary cases in households, seven were below the age of 15 years (three were aged 1-4 years, two were aged 5-9 years, and the remaining two were 10-14 years old). Three of the 13 household cases (23.1%) were partners of index cases (one of whom was a probable case) and were reported to have contracted mpox sexually from their partners; the remaining ten (76.9%) likely acquired infection through household contact. One of the cases infected in Europe was a healthcare worker who had cared for a case during treatment in hospital (Table 1).

Of the 20 autochthonous cases with no clear exposure to a reported case, one reported from France had no travel history but reported contact with her partner and another family member

who had both returned from a central African country in the previous 21 days; neither of them had reported symptoms compatible with MPXV infection. The source of infection for two additional cases (one in the United Kingdom and one in Germany) remains unknown (Table 1). Twenty-one cases reported since October 2025 were men who have sex with men (MSM) and who were reported to have contracted mpox sexually in the Netherlands (N=11), Spain (N=8), Malaysia (N=1), and United Arab Emirates (N=1); seven of these cases reported by the Netherlands and one reported by Belgium reported having attended the same sex venue in Amsterdam. These cases are the first evidence of MPXV clade Ib circulation in MSM sexual networks in Europe.

TABLE 1: Reported probable mode of transmission of MPXV clade I cases, WHO Member States, 14 August 2024 – 23 November 2025 (N=82)

Probable mode of transmission	Imported cases (N=45)	Autochthonous cases (N=37)		All cases (N=82)
		Household cases (N=13)	Other cases (N=24)	
Sexual contact	25	3	18	46
Other contact in household	0	10	0	10
Close physical contact (e.g. sauna, spa, massage)	4	0	0	4
Healthcare setting	0	0	1	1
Unknown	16	0	5[a]	21

[a] One of these three cases reported contact with family members who had travelled to an outbreak-affected country in Central Africa.

Of the 45 imported cases, information on whether the individual was returning to a household with other residents was available for 34; of these, 25 (73.5%) returned to households with

other residents, and transmission occurred in six of these households, resulting in thirteen additional cases among a total of 33 household contacts (attack rate in these six households: 39.4%, range 0-100%). Two household cases were determined to be possible second-generation transmission events; in one household, the case had symptom onset in January 2025 following two cases with symptom onset in the same household in December 2024, although transmission through fomites or an unidentified fourth household case could not be excluded. On another occasion, a probable imported case infected his wife sexually (attack rate: 12.5%), who then likely infected one of their children through close physical contact (secondary attack rate: 14.3%). Of 37 imported cases with information available, 15 (40.5%) travelled to Europe by air while symptomatic or with rash and, in at least one case, with an uncovered rash on their arms.

In all countries, contacts of mpox cases were identified and classified following a risk classification, in line with WHO [24] or national guidance. Follow-up of travel-related contacts according to WHO guidelines [24] was not consistent, but for one imported case the national health authorities asked the airline to contact the co-passengers after exposure to the case for about one hour.

Further information on the number of contacts in travel and school settings was sparse; no secondary case was reported among travel or school contacts.

Where information was available (N=65), subclade was confirmed a median of 10 days after symptom onset (-1 to 74 days); two patients were diagnosed before symptom onset due to active follow up following household exposure.

Contacts of already reported cases sought or received care quicker and were diagnosed sooner than imported cases or those autochthonous cases with no reported exposure to a known case (Table 2); nonetheless, contacts of known cases still took a median of 3.5 days after symptoms to seek care.

TABLE 2: Time to seeking care and to diagnosis of reported clade I MPXV cases, WHO EURO member states, 14 August 2024 – 23 November 2025

	Median delay from symptom onset to seeking care (range) (N=49)	Median delay from seeking care to subclade identification (range) (N=44)	Median delay from symptom onset to subclade identification (range) (N=65)
Imported cases	5.0 (1 to 15) days	6.0 (0 to 70) days	11 (2 to 74) days
Autochthonous cases with contact to already reported cases	3.5 (0 to 9 days)	5.0 (2 to 7) days	6.0 (-1 to 14) days
Autochthonous cases without contact to already reported cases	3.0 (2-15) days	5.5 (1 to 12) days	10 (4 to 21) days
All cases	5.0 (0 to 15) days	6.0 (0 to 70) days	10.0 (-1 to 74) days
Kruskal-Wallis test p-value	0.4509	0.8253	0.0092

Discussion

Since the declaration of a PHEIC in August 2024 and until 23 November 2025, 82 confirmed MPXV clade I cases have been reported in thirteen member states of the WHO European Region. Until October 2025, most cases were imported with some limited secondary and possibly tertiary transmission in household settings likely due to both sexual contact and close non-sexual physical contact, to partners and children. However, since October 2025, cases without links to travel, especially in the MSM community, have been increasing and indicate circulation of the virus in Europe [25, 26]. Sexual transmission of MPXV clade Ib, especially in MSM networks, appears to have become the most significant route of transmission of the subclade in Europe in recent weeks. While there is no evidence of sustained transmission in the general population at this stage, the situation is evolving. The experience from MPXV clade IIb suggests that the spillover risk for the general population remains quite limited.

We describe here also two cases of MPXV clade Ia infection, both with recent travel to the Democratic Republic of the Congo. One of the sequences contained mutational signature widely reported for MPXV clade IIb virus genomes during the 2022-2023 global outbreak. The presence of this host-driven mutagenesis pattern in a clade Ia virus suggests substantial person-to-person transmission [27].

Follow-up of flight passengers was often not performed; this highlights continued challenges in effective contact tracing of those exposed on aircrafts. Similarly, in line with existing evidence for MPXV clade IIb [28], our data suggests that there is limited evidence to support that at-scale MPXV clade I transmission took place in aircrafts. Disentangling transmission routes especially in a household setting was complicated by the sensitive nature of the infection and the multiple possibilities of contact and fomite use.

MPXV clade I infections have been previously thought to be more severe than clade II infections [11, 29]. However, in areas where MPXV clade Ib has become endemic, CFRs have been reported to be below 1%. Moreover, no deaths due to MPXV clade I infections have been reported in non-endemic countries with imported cases [11]; no death was observed among the cases reported in Europe that we describe here either.

Since 2023, the outbreak of MPXV clade I in the Democratic Republic of the Congo has substantially affected children [30]. In the cases we present here, many imported cases reported heterosexual contacts in outbreak-affected countries in Africa as the most prevalent transmission route. Of the 18 locally acquired cases of MPXV clade Ib in Europe, seven were among children under 15 years, whereas since 2022, only 38 locally acquired clade II cases in this age group, despite more than 33,000 cases of clade IIb in MSM [6]. This may reflect an overall difference in the presence of children and household size between imported MPXV clade Ia cases and the ongoing autochthonous spread among predominately men of MPXV clade IIb in the WHO European Region. More data is needed to see if these reported differences in transmission are due to contact patterns or virologic factors. Although active follow-up of contacts supported the identification of secondary cases in Europe, healthcare-seeking and diagnostic delays, especially among index cases, may have contributed to the limited transmission of MPXV clade I that has been reported. These delays were substantial in our case series (median of 6 days from seeking care to virus subclade identification and up to 70 days among imported cases). Clinicians in primary and acute care should consider mpox in patients with compatible symptoms regardless of travel history, and request PCR

with clade-specific typing at initial testing, given autochthonous clade Ib in Europe. The 3.5-day gap between symptom onset and seeking care among contacts of known cases was surprising despite the proactive investigation for more imported cases.

The outbreak in Central and East Africa, albeit declining, is ongoing, despite control efforts, including vaccination. While clade I continues to circulate in these regions, importations into the European Region are likely. The rate of importations to Europe has been somewhat reflective of the epidemic dynamics in countries most affected, with fewer isolated importations over the last few months. In Europe, the epidemiology of MPXV clade I is evolving. Available data suggests that, as for clade IIb, most detected transmission has occurred through importations from regions that are more affected, as well as sexual contact in MSM networks, with only sporadic household clusters and little evidence that non-sexual community transmission within Europe has made a substantial contribution to sustaining outbreaks. However, uncertainties remain regarding the extent of silent importations, age-specific risk, secondary attack rates, and vaccine-derived protection. For context, clade II transmission continues in Europe at low levels of 100-300 cases a month, mainly circulating in MSM sexual networks. An immediate priority in Europe is preventing the establishment of sustained clade I transmission, given sporadic importations and evidence of sexual network and limited household spread. As recent MPXV clade Ib spread in Europe has been largely driven by MSM sexual networks rather than isolated importations, understanding current immunity levels among high-risk groups is important. Although the PHEIC was lifted in September 2025, WHO Standing Recommendations [20] will remain key for countries to mitigate the establishment of clade I transmission and continue to advocate for better control of mpox.

Continued genomic surveillance with subtyping, early case identification, early diagnosis and systematic contact tracing, including timely cross-border information sharing, remain essential to reduce the risk of sustained MPXV clade I transmission in Europe and understanding virological evolution [7, 24]. Strengthening diagnostic capacity, including subtyping, is critical to detect and monitor emerging variants and guide appropriate public health measures [27, 31]; the recombinant virus reported by the United Kingdom would not have been identified without routine genomic surveillance [23]. Given the observed cases among a healthcare worker and within an MSM network, countries in Europe should ensure robust IPC in healthcare facilities and sustain engagement with MSM communities.

Finally, renewed efforts should be made to reach out to affected groups on the risk posed by mpox in different settings and the behavioural measures to reduce risk such as reducing parters, and safer sex practices. Continued efforts to reach out and offer vaccination to all risk groups, but especially to high-risk individuals who may play an outsized role in transmission within MSM networks.

Ethics/consent statement

This analysis used routinely collected surveillance data shared with WHO under the International Health Regulations. In line with WHO and national regulations, this public health practice activity did not require separate ethical committee review or individual informed consent.

Acknowledgments

We wish to thank Xanthi Andrianou and Gianfranco Spiteri from the European Centre for Disease Prevention and Control for critically reviewing this paper, as well as all colleagues in Europe working on mpox response at the national and subnational level for their continued contributions to surveillance.

References

1.   Heymann DL, Szczeniowski M, Esteves K. Re-emergence of monkeypox in Africa: a review of the past six years. Br Med Bull. 1998;54(3):693-702.

2.   Centers for Disease Control and Prevention. Multistate outbreak of monkeypox--Illinois, Indiana, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep. 2003;52(23):537-40.

3.   Petersen E, Abubakar I, Ihekweazu C, Heymann D, Ntoumi F, Blumberg L, et al. Monkeypox - Enhancing public health preparedness for an emerging lethal human zoonotic epidemic threat in the wake of the smallpox post-eradication era. Int J Infect Dis. 2019;78:78-84.

4.   World Health Organization. Disease Outbreak News - Monkeypox - Democratic Republic of the Congo. 2020. 2025-04-16. Available from: https://www.who.int/emergencies/disease-outbreak-news/item/monkeypox-democratic-republic-of-the-congo

5.   World Health Organization. WHO Director-General declares the ongoing monkeypox outbreak a Public Health Emergency of International Concern. 2022. 2025-04-16. Available from: https://www.who.int/europe/news/item/23-07-2022-who-director-general-declares-the-ongoing-monkeypox-outbreak-a-public-health-event-of-international-concern

6.   World Health Organization. Global Mpox Trends. 2025. 2025-04-16. Available from: https://worldhealthorg.shinyapps.io/mpx_global/#trends-in-cases

7.   Vaughan AM, Afzal M, Nannapaneni P, Leroy M, Andrianou X, Pires J, et al. Continued circulation of mpox: an epidemiological and phylogenetic assessment, European Region, 2023 to 2024. Euro Surveill. 2024;29(27).

8.   World Health Organization. Fifth Meeting of the International Health Regulations (2005) (IHR) Emergency Committee on the Multi-Country Outbreak of mpox (monkeypox). 2023. Available from: https://www.who.int/news/item/11-05-2023-fifth-meeting-of-the-international-health-regulations-%282005%29-%28ihr%29-emergency-committee-on-the-multi-country-outbreak-of-monkeypox-%28mpox%29

9.   The Lancet. Mpox: the need for a coordinated international response. The Lancet. 2024;404(10454):725.

10.   DeWitt ME, Polk C, Williamson J, Shetty AK, Passaretti CL, McNeil CJ, et al. Global monkeypox case hospitalisation rates: A rapid systematic review and meta-analysis. eClinicalMedicine. 2022;54.

11.   Vakaniaki EH, Kacita C, Kinganda-Lusamaki E, O'Toole Á, Wawina-Bokalanga T, Mukadi-Bamuleka D, et al. Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo. Nat Med. 2024;30:2791-5.

12.   World Health Organization. WHO Director-General declares mpox outbreak a public health emergency of international concern. 2024. Available from: https://www.who.int/europe/news/item/16-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern

13.   World Health Organization. WHO Director-General's opening remarks at the media briefing – 5 September 2025. 2025. 2025-09-11. Available from: https://www.who.int/news-room/speeches/item/who-director-general-s-opening-remarks-at-the-media-briefing---5-september-2025

14.   Treutiger C-J, Filén F, Rehn M, Aarum J, Jacks A, Gisslén M, et al. First case of mpox with monkeypox virus clade Ib outside Africa in a returning traveller, Sweden, August 2024: public health measures. Eurosurveillance. 2024;29(48):2400740.

15.   World Health Organization. Disease Outbreak News - Mpox - Sweden. 2024. 2025-09-11. Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON531

16.   Biller M, Lais J, Esser S, Sammet S. Unusual case of non-sexual Mpox transmission in a heterosexual woman. Infection. 2025.

17.   Malembi E, Escrig-Sarreta R, Ntumba J, Beiras CG, Shongo R, Bengehya J, et al. Clinical presentation and epidemiological assessment of confirmed human mpox cases in DR Congo: a surveillance-based observational study. Lancet. 2025;405(10490):1666-75.

18.   European Centre for Disease Prevention and Control. Risk assessment for the EU/EEA of the mpox epidemic caused by monkeypox virus clade I in affected African countries. 2024. 2025-12-17. Available from: https://www.ecdc.europa.eu/en/publications-data/risk-assessment-mpox-epidemic-monkeypox-virus-clade-i-africa

19.   Cabanillas B, Murdaca G, Guemari A, Torres MJ, Azkur AK, Aksoy E, et al. Monkeypox 2024 outbreak: Fifty essential questions and answers. Allergy. 2024;79(12):3285-309.

20.   World Health Organization. Extension of standing recommendations for mpox by the Director-General of WHO. 2025. Available from: https://www.who.int/publications/m/item/extension-of-standing-recommendations-for-mpox-by-the-director-general-of-who

21.   World Health Organization. International Health Regulations (2005) as amended in 2014 and 2022. 2022. Available from: https://apps.who.int/gb/bd/pdf_files/IHR_2022-en.pdf

22.   Dowling-Cullen C, Fahey L, Carr M, Keogan B, Hebert J, Muhamad Fauzi SM, et al. Mpox due to monkeypox virus clade Ia infection detected outside of Africa: a case study. Communications Medicine. 2025.

23.   UK Health Security Agency. New mpox strain identified in England. 2025. Available from: https://www.gov.uk/government/news/ukhsa-detects-first-case-of-clade-ib-mpox

24.   World Health Organization. Surveillance, case investigation and contact tracing for mpox: interim guidance, 27 November 2024. 2024. Available from: https://www.who.int/publications/i/item/B09169

25.   World Health Organization. Multi-country outbreak of mpox, External situation report #59 - 30 October 2025. 2025. Available from: https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report--59---30-october-2025

26.   European Centre for Disease Prevention and Control. Communicable disease threats report. Week 44, 25-31 October 2025. 2025. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Communicable-disease-threats-report-week-44-2025.pdf

27.   O'Toole Á, Neher RA, Ndodo N, Borges V, Gannon B, Gomes JP, et al. APOBEC3 deaminase editing in mpox virus as evidence for sustained human transmission since at least 2016. Science. 2023;382(6670):595-600.

28.   Delea KC CT, Lavilla K, Hercules Y, Gearhart S, Preston LE, et al. Contact Tracing for Mpox Clade II Cases Associated with Air Travel — United States, July 2021–August 2022. MMWR Morb Mortal Wkly Rep. 2024;73(35):758-62.

29.   Likos AM, Sammons SA, Olson VA, Frace AM, Li Y, Olsen-Rasmussen M, et al. A tale of two clades: monkeypox viruses. Journal of General Virology. 2005;86(10):2661-72.

30.   Nishtar S. The mpox emergency and the role of Gavi. The Lancet. 2024;404(10454):729-31.

31.   Atkinson B, Gould S, Nicholls I, Manzoor KN, Smith J, Hindle AJ, et al. Air and surface sampling for clade Ib monkeypox virus in United Kingdom hospitals, 2024 to 2025. Eurosurveillance. 2025;30(19):2500288.

32.   Alvi MI, Kliner M, Welfare W, Gordon NC, Thomas S, Padfield S, et al. Case series of the first five human infections with monkeypox virus clade Ib and report on the public

health response, United Kingdom, October to November 2024. Eurosurveillance. 2025;30(10):2500131.

Figure legends

Figure 1: Reported MPXV clade I cases and clusters, 14 August 2024 – 23 November 2025, WHO Regional Office for Europe (N=82).

Figures

Figure 1

Appendix: Supplementary Table S1: Characteristics of reported MPXV clade I cases by reporting WHO Member State, 14 August 2024 – 23 November 2025

Country	Age group (sex) of first reported case	Further reported local transmission	Size of cluster in the WHO European Region	Children ≤18 years affected in the WHO European Region	Mode of further transmission in the WHO European Region	Mode of transmission to the index case
Belgium	30-39 (M)	Yes	4	2	Household or fomites	Sexual contact
Belgium	30-39 (M)	No	1	0	N/A	Sexual contact
Belgium	30-39 (M)	No	1	0	N/A	Sexual contact
Belgium	18-29 (M)	No	1	0	N/A	Sexual contact
Belgium	30-39 (M)	No	1	0	N/A	Sexual contact
France	30-39 (F)	Yes	At least 2 (1 reported)	0	Sexual (improbable due to patient's history) or close contact	Unknown
France	40-49 (M)	No	1	0	N/A	Sexual contact

France	40-49 (F)	No	1	0	N/A	Unknown
France	18-29 (M)	No	1	0	N/A	Unknown
Germany	30-39 (M)	No	1	0	N/A	Sexual contact
Germany	40-49 (M)	Yes	4	2	Household	Unknown (physical contact in social settings reported)
Germany	50-59 (M)	No	1	0	N/A	Sexual contact
Germany	18-29 (M)	No	1	0	N/A	Unknown (physical contact at festival reported)
Germany	40-49 (M)	No	At least 2 (1 reported)	0	Unknown	Unknown
Germany	4049 (M)	Yes	2	0	Household	Unknown
Germany	18-29 (M)	No	1	0	N/A	Close physical contact
Germany	50-59 (M)	No	1	0	N/A	Sexual contact

Germany	18-29 (F)	No	1	0	N/A	Sexual contact
Germany	40-49 (M)	No	1	0	N/A	Unknown
Germany	40-49 (M)	No	1	0	N/A	Sexual contact
Greece	30-39 (M)	No	1	0	N/A	Sexual contact
Ireland (clade Ia)	30-39 (M)	No	1	0	N/A	Unknown
Ireland	18-29 (F)	Yes	4 (of which 3 confirmed)	1	Household and healthcare setting	Sexual contact
Italy	40-49 (M)	No	1	0	N/A	Unknown
Italy	40-49 (M)	No	1	0	N/A	Sexual contact
Italy	Unknown (M)	No	1	0	N/A	Unknown
Italy	Unknown (M)	No	1	0	N/A	Unknown
the Netherlands	30-39 (M)	No	1	0	N/A	Sexual contact
the Netherlands	30-39 (M)	Yes	2	0	Sexual contact	Sexual contact

the Netherlands	18-29 (M)	No	1	0	N/A	Sexual contact
the Netherlands	30-39 (M)	No	1	0	N/A	Sexual contact
the Netherlands	60-69 (M)	No	1	0	N/A	Sexual contact
the Netherlands	50-59 (M)	No	1	0	N/A	Sexual contact
the Netherlands	30-39 (M)	No	1	0	N/A	Sexual contact
the Netherlands	30-39 (M)	No	1	0	N/A	Sexual contact
Portugal	30-39 (M)	No	1	0	N/A	Sexual contact
Spain	30-39 (M)	No	1	0	N/A	Sexual contact
Spain	40-49 (M)	No	At least 2 (1 reported)	0	N/A	Sexual contact
Spain (clade I)	40-49 (M)	No	1	0	N/A	Sexual contact

Spain (clade I)	50-59 (M)	No	1	0	N/A	Sexual contact
Spain	30-39 (M)	No	1	0	N/A	Sexual contact
Spain	50-59 (M)	No	1	0	N/A	Sexual contact
Spain	18-29 (M)	No	1	0	N/A	Sexual contact
Spain	18-29 (M)	No	1	0	N/A	Sexual contact
Spain	18-29 (M)	No	1	0	N/A	Sexual contact
Sweden	30-39 (M)	No	1	0	N/A	Unknown
Switzerland	40-49 (M)	No	1	0	N/A	Sexual contact
United Kingdom	40-49 (M)	Yes, 3 household contacts (1 partner and 2 children)	4	2	Close physical contact, household contact	Close physical contact [32]
United Kingdom	18-29 (M)	No	1	0	N/A	Sexual contact [32]
United Kingdom	60-69 (M)	No	1	0	N/A	Sexual contact
United Kingdom	60-69 (M)	No	1	0	N/A	Unknown

United Kingdom	18-29 (M)	No	1	0	N/A	Sexual contact
United Kingdom	18-29 (M)	No	1	0	N/A	Sexual contact
United Kingdom	30-39 (M)	No	1	0	N/A	Close physical contact
United Kingdom	18-29 (M)	No	At least 2 (1 reported)	0	N/A	Unknown
United Kingdom	30-39 (M)	No	1	0	N/A	Close physical contact
United Kingdom	50-59 (M)	Yes	2	0	Close contact, household contact	Unknown
United Kingdom	50-59 (M)	No	1	0	N/A	Sexual contact
United Kingdom	18-29 (M)	No	1	0	N/A	Sexual contact
United Kingdom	18-29 (M)	No	1	0	N/A	Unknown
United Kingdom*	40-49 (M)	No	1	0	N/A	Sexual contact
United Kingdom	30-39 (M)	No	1	0	N/A	Sexual contact

Türkiye (clade Ia)	18-29 (M)	No	1	0	N/A	Unknown
Türkiye	30-39 (M)	No	1	0	N/A	Sexual contact
Türkiye	30-39 (M)	No	1	0	N/A	Unknown
Türkiye	18-29 (M)	No	1	0	N/A	Sexual contact
Türkiye	40-49 (M)	No	1	0	N/A	Unknown

N/A: "not available"

* recombinant virus with elements of both MPXV clade Ib and MPXV clade IIb [23]